CYCN vs. ATHE, VIRI, CMMB, BNOX, CLVR, LGVN, TRVN, TNXP, PTIX, and CANF
Should you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Alterity Therapeutics (ATHE), Virios Therapeutics (VIRI), Chemomab Therapeutics (CMMB), Bionomics (BNOX), Clever Leaves (CLVR), Longeveron (LGVN), Trevena (TRVN), Tonix Pharmaceuticals (TNXP), Protagenic Therapeutics (PTIX), and Can-Fite BioPharma (CANF). These companies are all part of the "pharmaceutical preparations" industry.
Cyclerion Therapeutics (NASDAQ:CYCN) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment.
In the previous week, Alterity Therapeutics had 5 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 6 mentions for Alterity Therapeutics and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat Alterity Therapeutics' score of 0.14 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.
75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 13.1% of Cyclerion Therapeutics shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Alterity Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 246.53%. Given Alterity Therapeutics' higher probable upside, analysts plainly believe Alterity Therapeutics is more favorable than Cyclerion Therapeutics.
Cyclerion Therapeutics has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.
Cyclerion Therapeutics has higher earnings, but lower revenue than Alterity Therapeutics.
Alterity Therapeutics' return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.
Cyclerion Therapeutics received 31 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. However, 60.00% of users gave Alterity Therapeutics an outperform vote while only 58.62% of users gave Cyclerion Therapeutics an outperform vote.
Summary
Alterity Therapeutics beats Cyclerion Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Cyclerion Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cyclerion Therapeutics Competitors List
Related Companies and Tools